|
Status |
Public on Oct 24, 2020 |
Title |
OCI-LY10 50µM IRAKi 6h |
Sample type |
RNA |
|
|
Source name |
OCI-LY10 50µM IRAKi 6h
|
Organism |
Homo sapiens |
Characteristics |
cell line: OCI-LY10 treatment: IRAKi time: 6h
|
Treatment protocol |
ABC-DLBCL cells were treated with 50µM IRAKI for 6h +/- CPI203 500nM for 18h
|
Growth protocol |
ABC-DLBCL cells at exponential phase were set at 1x10e6 cells/ml for the experiment
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted using the Trizol reagent
|
Label |
biotin
|
Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 150 ng total RNA
|
|
|
Hybridization protocol |
RNA samples were processed to Affymetrix GeneChip HT HG-U219 arrays.
|
Scan protocol |
Scanning was processed in the Gene Titan instrument.
|
Description |
OCI-LY10 IRAKi
|
Data processing |
Determination of the signal value for each probe set of the array were obtained with GeneChip® Command Console® Software (AGCC) (Affymetrix). Raw data were normalized using the Robust Multichip Analysis (RMA) algorithm implemented in the Expression Console Software v1.1 (Affymetrix).
|
|
|
Submission date |
Oct 23, 2020 |
Last update date |
Oct 24, 2020 |
Contact name |
Gael Roue |
E-mail(s) |
[email protected]
|
Organization name |
Josep Carreras Leukaemia Research Institute
|
Department |
Lymphoma Translational lab
|
Street address |
Ctra de Can Ruti, Camí de les Escoles s/n
|
City |
Badalona |
ZIP/Postal code |
08916 |
Country |
Spain |
|
|
Platform ID |
GPL13667 |
Series (1) |
GSE159915 |
IRAK1/4 and BET bromodomain inhibitions converge on NF-κB blockade and display synergistic antitumor activity in ABC-DLBCL with MYD88L265P mutation |
|